The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 4 rounds in the feed, most often at Series A and in Biotech.
Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence.
Venture capitaldecheng.comRounds from 2021-05-05 to 2026-09-28
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Synphatec CNS Innovative Drug Developer | Series A Verified against 3 sources | $50M | 2026-09-28 | [ LEAD ] |
Cellares Cellares specializes in advanced manufacturing technologies for cell therapy, targeting biopharmaceutical companies and healthcare providers. | Series C Verified against 2 sources |
| $255M |
| 2023-08-23 |
| [ PART ] |
Solve Therapeutics Novel antibody-drug conjugates (ADCs) for cancer treatment targeted at solid tumors and optimized for payload delivery using proprietary technology. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $126M | 2022-12-14 | [ PART ] |
Cellares Cellares specializes in advanced manufacturing technologies for cell therapy, targeting biopharmaceutical companies and healthcare providers. | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $82M | 2021-05-05 | [ LEAD ] |